Genocea Biosciences Inc ROCE
Was ist das ROCE von Genocea Biosciences Inc?
ROCE von Genocea Biosciences Inc ist -175.11%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Genocea Biosciences Inc
Was macht Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Unternehmen mit roce ähnlich Genocea Biosciences Inc
- UrbanGold Minerals hat ROCE von -176.34%
- Elys Game Technology hat ROCE von -176.22%
- Biohaven Ltd hat ROCE von -175.96%
- Asiamet Resources hat ROCE von -175.74%
- Elsight hat ROCE von -175.70%
- Capricor Therapeutics Inc hat ROCE von -175.51%
- Genocea Biosciences Inc hat ROCE von -175.11%
- Sanibel Ventures hat ROCE von -175.10%
- Workhorse Inc hat ROCE von -174.48%
- Greenwich LifeSciences hat ROCE von -173.92%
- Lordstown Motors hat ROCE von -173.29%
- Satsuma Pharmaceuticals hat ROCE von -172.20%
- Oncopeptides AB (publ) hat ROCE von -172.14%